Initial clinical radiological findings and staging to predict prognosis of primary hepatic angiosarcoma: A retrospective analysis


Autoři: Wei-Hsin Yuan aff001;  Anna Fen-Yau Li aff002;  Hui-Chen Hsu aff005;  Yong-Sin Hu aff002;  Rheun-Chuan Lee aff002
Působiště autorů: Division of Radiology, Taipei Municipal Gan-Dau Hospital (managed by Taipei Veterans General Hospital), Taipei, Taiwan, Republic of China aff001;  School of Medicine, National Yang Ming University, Taipei, Taiwan, Republic of China aff002;  Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China aff003;  Department of Pathology, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China aff004;  Department of Medical Imaging, Taiwan Adventist Hospital, Taipei, Taiwan, Republic of China aff005
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
doi: 10.1371/journal.pone.0225043

Souhrn

Objective

Primary hepatic angiosarcoma (PHA) is extremely rare and most patients die within 12 months of diagnosis. The object of the study is to determine the association of initial clinical-radiological features and staging with outcomes in patients with PHA.

Methods

The medical records of adult patients with PHA were retrieved from an electronic medical record database and a pathology database and retrospectively reviewed. During 10 years, 22 eligible patients were included. Data extracted focused on the information before the first formal treatment with a pathological proof, including demographic characteristics, medical history, laboratory data, preliminary images, histopathological records, treatment, and follow-up survival period. Two radiologists blindly re-analyzed preliminary images of all 22 patients together and recorded tumor features and imaging stage based on the American Joint Committee on Cancer (AJCC) 8th edition tumor-node-metastasis (TNM) Staging System for hepatocellular carcinoma. A radiologist compiled the initial clinical data and preliminary image stage to analyze the association with patients’ survival outcome.

Results

Higher aspartate aminotransferase (AST), higher total bilirubin (TB), lower albumin (ALB), longer prothrombin time (PT) and lower platelet count of serum relative to the normal reference range were more common in patients who survived ≤ 90 days (all P < 0.05). Overall survival was much better in patients with single PHA than in those with other tumor patterns of multiple PHA (all P < 0.05). Overall survival determined by preliminary imaging showed significant differences between stage I and stage III (P = 0.044), stage I and stage IV (P = 0.011), and stage III and IV (P = 0.047). No patients were at stage II.

Conclusions

Initial serum levels of ALT, TB, ALB, and PT, platelet count, single mass in liver, and preliminary imaging staging could help predict survival outcomes of patients with PHA.

Klíčová slova:

Angiosarcoma – Cancer treatment – Computed axial tomography – Hepatocellular carcinoma – Lesions – Magnetic resonance imaging – Platelets – Liver and spleen scan


Zdroje

1. Koyama T, Fletcher JG, Johnson CD, Kuo MS, Notohara K, Burgart LJ. Primary hepatic angiosarcoma: findings at CT and MR imaging. Radiology. 2002;222:667–673. doi: 10.1148/radiol.2223010877 11867783

2. Kamath SM, Mysorekar VV, Kadamba P. Hepatic angiosarcoma developing in an infantile hemangioendothelioma: A rare case report. J Cancer Res Ther. 2015;11:1022.

3. Huang NC, Kuo YC, Chiang JC, Hung SY, Wang HM, Hung YM, et al. Hepatic angiosarcoma may have fair survival nowadays. Medicine (Baltimore). 2015;94:e816.

4. Kim HR, Rha SY, Cheon SH, Roh JK, Park YN, Yoo NC. Clinical features and treatment outcomes of advanced stage primary hepatic angiosarcoma. Ann Oncol. 2009;20:780–787. doi: 10.1093/annonc/mdn702 19179547

5. Ling W, Qiu T, Ma L, Lei C, Luo Y. Contrast-enhanced ultrasound in diagnosis of primary hepatic angiosarcoma. J Med Ultrason (2001). 2017;44:267–270.

6. Lau EKC, Tsai B, Morrison H, Deftos M, Lin AY. Metachronous Hepatic Angiosarcoma Presenting as a Mimic of Recurrent Hepatocellular Carcinoma. J Gastrointest Cancer. 2019;50(3):647–650. doi: 10.1007/s12029-018-0094-3 29623568

7. Lin YH, Lin CC, Concejero AM, Yong CC, Kuo FY, Wang CC. Surgical experience of adult primary hepatic sarcomas. World J Surg Oncol. 2015;13:87. doi: 10.1186/s12957-015-0489-6 25880743

8. Zheng YW, Zhang XW, Zhang JL, Hui ZZ, Du WJ, Li RM, et al. Primary hepatic angiosarcoma and potential treatment options. J Gastroenterol Hepatol. 2014;29:906–911. doi: 10.1111/jgh.12506 24372769

9. Qiao Y, Yang J. Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report. BMC Cancer. 2018;18:212. doi: 10.1186/s12885-018-3996-3 29466964

10. Weitz J, Klimstra DS, Cymes K, Jarnagin WR, D’Angelica M, La Quaglia MP, et al. Management of primary liver sarcomas. Cancer. 2007;109:1391–1396. doi: 10.1002/cncr.22530 17315167

11. Huang IH, Wu YY, Huang TC, Chang WK, Chen JH. Statistics and outlook of primary hepatic angiosarcoma based on clinical stage. Oncol Lett. 2016;11:3218–3222. doi: 10.3892/ol.2016.4348 27123094

12. Murphy BJ, Casillas J, Ros PR, Morillo G, Albores-Saavedra J, Rolfes DB. The CT appearance of cystic masses of the liver. Radiographics. 1989;9(2):307–322. doi: 10.1148/radiographics.9.2.2538868 2538868

13. Slebocki K, Kraus B, Chang DH, Hellmich M, Maintz D, Bangard C. Incidental findings in abdominal dual-energy computed tomography: correlation between true noncontrast and virtual noncontrast images considering renal and liver cysts and adrenal masses. J Comput Assist Tomogr. 2017;41(2):294–297. doi: 10.1097/RCT.0000000000000503 27759598

14. Gaballah AH, Jensen CT, Palmquist S, Pickhardt PJ, Duran A, Broering G, et al. Angiosarcoma: clinical and imaging features from head to toe. Br J Radiol. 2017;90(1075):20170039 doi: 10.1259/bjr.20170039 28471264

15. Wang H, Shi J, Liu H, Chen Y, Wang Y, Wang W, et al. Clinical and diagnostic features of angiosarcoma with pulmonary metastases: A retrospective observational study. Medicine (Baltimore). 2017;96(36):e8033.

16. Bruegel M, Muenzel D, Waldt S, Specht K, Rummeny EJ. Hepatic angiosarcoma: cross-sectional imaging findings in seven patients with emphasis on dynamic contrast-enhanced and diffusion-weighted MRI. Abdom Imaging. 2013;38:745–754. doi: 10.1007/s00261-012-9967-2 23223833

17. Pickhardt PJ, Kitchin D, Lubner MG, Ganeshan DM, Bhalla S, Covey AM. Primary hepatic angiosarcoma: multi-institutional comprehensive cancer centre review of multiphasic CT and MR imaging in 35 patients. Eur Radiol. 2015;25:315–322. doi: 10.1007/s00330-014-3442-0 25278246

18. Katyal S, Oliver JH 3rd, Peterson MS, Ferris JV, Carr BS, Baron RL. Extrahepatic metastases of hepatocellular carcinoma. Radiology. 2000;216:698–703. doi: 10.1148/radiology.216.3.r00se24698 10966697

19. Pan T, Xie QK, Lv N, Li XS, Mu LW, Wu PH, et al. Percutaneous CT-guided Radiofrequency Ablation for Lymph Node Oligometastases from Hepatocellular Carcinoma: A Propensity Score-matching Analysis. Radiology. 2017;282:259–270. doi: 10.1148/radiol.2016151807 27399327

20. Chaudhary P, Bhadana U, Singh RA, Ahuja A. Primary hepatic angiosarcoma. Eur J Surg Oncol. 2015;41:1137–1143. doi: 10.1016/j.ejso.2015.04.022 26008857

21. Kalva SP, Sutphin PD. Invited Commentary: (90)Y Radioembolization. Radiographics. 2015;35:1618–1620. doi: 10.1148/rg.2015140333 26230756

22. Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology. 2002;123:1367–1384. doi: 10.1053/gast.2002.36061 12360498

23. Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol. 2005;42(Suppl 1):100–107.

24. Poon RT, Fan ST, Ng IO, Wong J. Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification. Ann Surg. 2003;237:376–383. doi: 10.1097/01.SLA.0000055224.68432.80 12616122

25. Chung YE, Kim MJ, Park YN, Choi JY, Pyo JY, Kim YC, et al. Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. Radiographics. 2009;29:683–700. doi: 10.1148/rg.293085729 19448110

26. Dehal AN, Graff-Baker AN, Vuong B, Nelson D, Chang SC, Lee DY, et al. Correlation Between Clinical and Pathologic Staging in Colon Cancer: Implications for Neoadjuvant Treatment. J Gastrointest Surg. 2018;22(10):1764–1771. doi: 10.1007/s11605-018-3777-y 29790087

27. Konstantinidis IT, Nota C, Jutric Z, Ituarte P, Chow W, Chu P, et al. Primary liver sarcomas in the modern era: Resection or transplantation? J Surg Onco. 2018;117(5):886–891.

28. Wu CH, Chiu NC, Yeh YC, Kuo Y, Yu SS, Weng CY, et al. Uncommon liver tumors: Case report and literature review. Medicine (Baltimore). 2016;95:e4952.

29. Kuei A, Saab S, Cho SK, Kee ST, Lee EW. Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors. World J Gastroenterol. 2015;21:8271–8283. doi: 10.3748/wjg.v21.i27.8271 26217079

30. Pierce DB, Johnson GE, Monroe E, Loggers ET, Jones RL, Pollack SM, et al. Safety and Efficacy Outcomes of Embolization in Hepatic Sarcomas. AJR Am J Roentgenol. 2018;210:175–182. doi: 10.2214/AJR.16.17573 29090997


Článek vyšel v časopise

PLOS One


2019 Číslo 11